Replies to post #221362 on Biotech Values

[DewDiligence]

Mavyret’s US new-patient share reached 54%—the highest-ever weekly figure—in the week ending 10/19/18, according to IMS.

I do not yet have the data on Mavyret’s US total-script share, or the market-share numbers for GILD and MRK.